Table 2.
Group | FAD | Juvenile FAD | Benign PT | Borderline PT | Malignant PT | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
N | % | N | % | N | % | N | % | N | % | ||
PAM50 | Basal‐like | 0 | 0% | 1 | 20% | 0 | 0% | 0 | 0% | 10 | 91% |
Luminal A | 1 | 4% | 0 | 0% | 1 | 5% | 0 | 0% | 0 | 0% | |
Normal | 25 | 96% | 4 | 80% | 18 | 95% | 5 | 100% | 1 | 9% | |
Total | 26 | – | 5 | – | 19 | – | 5 | – | 11 | – | |
PAM50 + Claudin‐low | Basal‐like | 0 | 0% | 1 | 20% | 0 | 0% | 0 | 0% | 3 | 27% |
Claudin‐low | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 7 | 64% | |
Luminal A | 1 | 4% | 0 | 0% | 1 | 5% | 0 | 0% | 0 | 0% | |
Normal | 25 | 96% | 4 | 80% | 18 | 95% | 5 | 100% | 1 | 9% | |
Total | 26 | – | 5 | – | 19 | – | 5 | – | 11 | – | |
PAM50‐ROR | High | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 8 | 73% |
Med | 2 | 8% | 2 | 40% | 1 | 5% | 2 | 40% | 3 | 27% | |
Low | 24 | 92% | 3 | 60% | 18 | 95% | 3 | 60% | 0 | 0% | |
Total | 26 | – | 5 | – | 19 | – | 5 | – | 11 | – |